



Prevention, Diagnostic and Antibiotic Treatment of Periprosthetic Joint and Fracture Related Infection, 2nd Edition

Guest Editors:

Prof. Dr. Bernd Fink

Department for Joint Replacement, Rheumatoid and General Orthopaedics, Orthopaedic Clinic Markgröningen, Markgröningen, Germany

Prof. Dr. Steffen Ruchholtz

Center for Orthopedics and Trauma Surgery, University Hospital of Marburg, Marburg, Germany

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editors

The aim of this Special Issue is to update the readers with new knowledge about the prevention, diagnostics, surgical and antibiotic treatment of periprosthetic joint and fracture-related infections.

Periprosthetic joint infection (PJI) and fracture-related infection (FRI) are severe complications of joint replacement and trauma surgery. Due to increasing numbers of joint replacements and revision arthroplasties, as well as fracture treatment, the number of PJIs and FRIs increase parallelly. Therefore, the prevention of this severe, expensive and resource-consuming complication is of high importance. Because no test with an accuracy of 100% exists, the diagnosis of possible infection remains a challenge.

Therefore, we are pleased to invite you to send papers discussing a topic in the field of PJI or FRI prevention, diagnosis and treatment. Original articles or meta-analyses in the clinical field and basic research are welcome, as well as review articles that summarize up-to-date knowledge in the field of this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi